Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet(扶正化瘀片) and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial

Zheng-xin LI; Zhi-min ZHAO; Ping LIU; Qing-shan ZHENG; Cheng-hai LIU

doi:10.1007/s11655-020-3257-6

Your Location：

Home >

Browse articles >

Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet(扶正化瘀片) and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial

Original Article | Updated：2021-09-01

- Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet(扶正化瘀片) and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial
- Chinese Journal of Integrative Medicine Vol. 27, Issue 7, Pages: 509-513(2021)
- Affiliations：
  
  1.Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai (201203), China
  2.Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai (200000), China
- Author bio：
  
  Prof. LIU Cheng-hai, E-mail: chenghai.liu@outlook.com
- Funds：
- DOI：10.1007/s11655-020-3257-6
  CLC：
- Published：01 July 2021，
  
  Published Online：22 June 2020，
  
  Accepted：15 January 2019
Scan for full text
Zheng-xin LI, Zhi-min ZHAO, Ping LIU, et al. Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet(扶正化瘀片) and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial. [J]. Chinese Journal of Integrative Medicine 27(7):509-513(2021)
DOI：

Zheng-xin LI, Zhi-min ZHAO, Ping LIU, et al. Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet(扶正化瘀片) and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial. [J]. Chinese Journal of Integrative Medicine 27(7):509-513(2021) DOI： 10.1007/s11655-020-3257-6.

摘要

Abstract

Background:

Antiviral therapy can lead to regression of fibrosis in chronic hepatitis B (CHB)

but it has a limited effect on cirrhosis. Chinese medicines (CMs)

particularly Fuzheng Huayu Tablet (扶正化瘀片

FZHY)

have an antifibrotic effect in patients with CHB.

Objective:

To observe the safety and efficacy of adjunctive FZHY in patients with hepatitis B virus (HBV) cirrhosis

this study was designed as a randomized

placebo-controlled

double-blind

parallel assignment

multicenter trial at 20 centers in China. The total 700 naive patients will be enrolled with compensate cirrhosis due to HBV

and randomly assigned into 2 groups

receiving entecavir (0.5 mg

daily) and FZHY placebo (1.6 g

3 times a day)

or entecavir (0.5 mg

daily ) and FZHY (1.6 g

3 times a day)

respectively. The primary endpoint was histological improvement at week 48. The secondary outcome is the decline values of liver fibrosis using the noninvasive methods from baseline to week 48 in each arm of the study. Adverse events such as stomach upset

headache

fatigue

dizziness

nausea will be strictly recorded.

Discussion:

Through this study

we hope to generate a solid evidence for the therapeutic strategy of HBV cirrhosis with a combination of anti-viral such as ETV and anti-fibrotic herbal product such as FZHY. Protocol version: Version 1.3

Date: 2014.12.4. Trial registration number: NCT02241590.

关键词

Keywords

chronic hepatitis Bliver fibrosisFuzheng Huayu Tabletrandomized multicenter trialtrial protocol

references

SK Sarin, M Kumar, GK Lau, Z Abbas, HL Chan, CJ Chen, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.

K Honda, M Seike, K Murakami. Benefits of nucleos(t) ide analog treatments for hepatitis B virus-related cirrhosis. World J Hepatol 2015;7:2404-2410.

S Kose, B Tatar, S Gul, E Pala. The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B. Acta Clin Belg 2016;71:244-249.

IC Wu, CL Lai, SH Han, KH Han, SC Gordon, YC Chao, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010;51:1185-1189.

TT Chang, RG Gish, R de Man, A Gadano, J Sollano, YC Chao, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893.

TT Chang, RG Gish, R de Man, A Gadano, J Sollano, YC Chao, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.

P Marcellin, E Gane, M Buti, N Afdhal, W Sievert, IM Jacobson, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.Lancet 2013;381:468-475.

B Xu, L Lin, G Xu, Y Zhuang, Q Guo, Y Liu, et al. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2015;30:372-378.

P Liu, YY Hu, C Liu. Multicenter clinical study on Fuzheng Huayu Capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol 2005;11:2892-2899.

T Hassanein, TD Box, MJ Tong, R Pozza, L Rossaro, et al. A phase Ⅱ, randomized, placebo-controlled, double-blind, multi-center study to assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis (S-USIIT-01).Gastroenterology 2014; 146: S261.

JD Jia, LJ Li. Guideline of prevention and treatment for chronic hepatitis B (2010). J Clin Hepatol (Chin) 2010;27:113-128.

K Ishak, A Baptista, L Bianchi, F Callea, J De Groote, F Gudat, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.

QL Wang, YY Tao, L Shen, HY Cui, CH Liu. Chinese herbal medicine Fuzheng Huayu Recipe inhibits liver fibrosis by mediating the transforming growth factor-beta1/Smads signaling pathway. J Chin Integr Med (Chin) 2012;10:561-568.

CH Liu, YY Hu, LM Xu, C Liu, P Liu. Effect of Fuzheng Huayu Formula and its actions against liver fibrosis. Chin Med 2009;4:12.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Efficacy of Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B Cirrhosis/Liver Fibrosis: A Randomized Double-Blind Controlled Trial

Related Author

No data

Related Institution

China Traditional Chinese Medicine Holdings Co. Limited

Central of Integrated Chinese and Western Medicine, Beijing Ditan Hospital, Capital Medical University

Peking University Ditan Teaching Hospital

National Center for Infectious Diseases

Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Disease, Beijing Ditan Hospital, Capital Medical University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰